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Abstract
Background: It has been estimated that as many as two thirds of patients with schizophrenia are unable to
perform basic personal and social roles or activities. Occupational functioning and social functioning, as well as
independent living, are considered as core domains of patient functioning. Improvement in patient functioning has
also been recognized as an important treatment goal in guidelines and an important outcome by regulatory
agencies. Nevertheless, information is lacking on how these aspects are being considered by psychiatrists across the
world and how they are being assessed and managed.
Methods: The ‘Europe, the Middle East and Africa functioning survey’ was designed to canvas opinions of
psychiatrists across these regions to ascertain their perceptions of the clinical importance, assessment and
management of functioning amongst their patients with schizophrenia. The survey comprised 17 questions and
was conducted from March to April 2011 in 42 countries. Data collected included the demographics of
respondents and their opinions regarding personal and social functioning in patients with schizophrenia.
Results: Results were obtained from 4,163 clinicians. Psychiatrists estimated that more than two thirds (70%) of
their patients with schizophrenia showed impaired or very poor levels of functioning. The majority of psychiatrists
(92%) believed that personal and social functioning was an important treatment goal for patients with
schizophrenia, and 91% believed it was an important goal for patients’ families. The majority of psychiatrists (55%)
assess the personal and social functioning of their patient at each visit; however, 81% reported that they determine
the level of functioning through clinical interview and not by using a specific assessment scale. To manage
personal and social functioning in their patients, 26% of psychiatrists prefer pharmacological interventions, whereas
46% prefer psychosocial interventions.
Conclusion: Psychiatrists recognize that functioning is impaired/very poor in patients with schizophrenia, and there
is still an important need to address functioning as a main treatment goal for patients with schizophrenia.
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Background
Schizophrenia is a complex and heterogeneous disorder,
with a range of symptoms and effects on the lives of pa-
tients and their families [1,2]. It impacts to a significant
and detrimental extent on patient functioning; indeed,
this deficit in functioning is recognized as a diagnostic
criterion of schizophrenia [3]. Several domains of func-
tioning are affected, including occupational and social
aspects and independent living [4,5].
Social functioning, in particular, is widely recognized as
an important factor when considering long-term outcomes
in patients with schizophrenia [6-8]. In one study of pa-
tients in six European centres, impairments in social func-
tioning were observed in over 78% of the population at
assessment within 2 years of first-episode psychosis, and
this persisted at subsequent 1-, 2- and 15-year follow-ups
[9]. Up to two thirds of patients are unable to perform
basic social roles, even when psychotic symptoms are in re-
mission; only a minority marry, and less than one third are
in regular employment [10]. There are regional differences
in employment rates amongst patients with schizophrenia
that may be linked in part to social or environmental influ-
ences such as local welfare or benefit systems, legislative
and economic factors [11]. A US study found the number
of patients with schizophrenia in regular, paid employment
to be less than 15%. In addition, unemployed patients
presented with lower quality of life scores, and an inverse
relationship existed between the likelihood of employment
and the receipt of disability payments [12]. Poor function-
ing therefore places a considerable burden (including an
economic impact) on society [8,10].
Improvement in functioning in patients with schizophre-
nia is now considered to be an important treatment goal
[13-15]. As such, it is included in treatment guidelines
[1,8,16] and has been recognized as a useful endpoint in
the evaluation of treatment options by regulatory author-
ities [17]. A recent literature review highlighted an increase
in the number of studies documenting symptomatic re-
mission and an awareness of functioning and quality of life
as outcome measures [18]. A number of studies have re-
ported improved patient functioning following treatment
with antipsychotics [19-24] or with non-pharmacological
interventions such as social skills training, cognitive behav-
ioural therapy, cognitive therapy, cognitive remediation
and social cognition training [25-27]. Improved social and
occupational functioning is also identified by patients and
their families as an important treatment outcome [10], as
well as by groups representing patients [6].
The remission of positive and negative symptoms does
not always correspond with an improvement in function-
ing [6,15,28,29], and improvements in symptoms do not
always correlate with patient satisfaction or with perform-
ance in social relationships or performance of daily ac-
tivities [30]. In one study, 3 years after beginning initial
antipsychotic treatment, symptomatic remission rates
were 60.3%, functional remission rates (defined by em-
ployment status, social relationships and independent liv-
ing) were 45.4%, and 57% of patients achieved adequate
subjective well-being. However, only 28.1% achieved re-
mission in all three areas [31]. Social functioning may,
therefore, represent an area that requires treatment be-
yond the resolution of overt symptoms of psychosis [32].
Conversely, early improvements in social functioning [33]
or subjective well-being may be predictors of symptomatic
remission [34] and of a good overall treatment outcome,
supporting the importance of assessing social functioning
in patients with schizophrenia [33]. Methods of gathering
information in order to assess functioning are, however,
known to vary and can include the perceptions or ratings
of health care professionals, patients and family members
[10,35]. While a number of assessment scales are used, in-
cluding the Social and Occupational Functioning Assess-
ment Scale (SOFAS) [36], the Functional Remission Of
General Schizophrenia (FROGS) scale [37], the Global As-
sessment of Functioning (GAF) scale [38] and the Personal
and Social Performance (PSP) scale [39], there is a lack of
standardization in methodology, as highlighted by several
authors [6,7,10,13,40].
Improved social functioning is an important treatment
goal for patients with schizophrenia which does not neces-
sarily correlate with improvement in disease symptoms.
Despite the prevalence of impaired functioning, assess-
ments of functional outcome are neither routinely con-
ducted nor effectively standardized in clinical practice. As
such, some authors recommend a change in current atti-
tudes and perceptions with respect to the importance,
evaluation and treatment of impairments in functioning
[32]. Results from a survey previously conducted in Spain
designed to assess the opinions and perceptions regarding
functioning in patients with schizophrenia highlighted a
need to obtain a broader understanding of the assessment
of the measurement and treatment of patient functioning
[41]. Results showed that psychiatrists considered the con-
trol of psychotic symptoms as the most important treat-
ment objective, with outcomes such as functioning and
relapse prevention regarded as secondary therapeutic ob-
jectives. Ninety-two percent of psychiatrists considered
that functioning should be recorded in medical notes; only
17% of the psychiatrists surveyed used specific scales to
assess their patients' functioning. Thirty-three percent of
respondents thought that <20% of their patients had an
adequate level of functioning, and 76% considered that pa-
tient functioning would be best improved by modifying
pharmacological treatment. Overall, this survey showed
that clinicians' perception of the level of functioning in
their patients with schizophrenia was low and that there is
a need to develop protocols to improve patient function-
ing [41]. How this type of perception applies in other
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countries (from Europe and elsewhere) is an important
consideration in relation to improving the following: (1)
the quality of assessment of patient functioning by psychi-
atrists, (2) the frequency of appropriate assessments of
the patients' autonomy and (3) the knowledge and use
of available therapeutic techniques that facilitate such
processes.
The present survey was performed across countries in
Europe, the Middle East and Africa, and aimed to deter-
mine psychiatrists' perceptions of the importance of social
functioning in their patients, the ways in which deficits are
assessed and managed and potential barriers to improving
social functioning in patients with schizophrenia.
Methods
This study aimed to investigate psychiatrists' opinions
and perceptions of functioning in their patients with
schizophrenia. A paper-based survey was conducted
amongst psychiatrists (and neurologists with a psychi-
atric background in Germany) treating patients with
schizophrenia in 42 countries, between March and April
2011, to document the management of social function-
ing across Europe, the Middle East and Africa.
A scientific committee of international experts with a
special interest in the functioning of patients with
schizophrenia developed a survey specifically to conduct
in Europe, the Middle East and Africa to understand fur-
ther psychiatrists’ opinions and perceptions of function-
ing in patients with schizophrenia. The survey consisted
of 17 questions, 4 relating to the demographic profile of
respondents and the remaining 13 regarding the extent
of impaired functioning seen in clinical practice, the role
of personal and social functioning as a treatment goal,
and approaches to the assessment and management of
personal and social functioning in patients with schizo-
phrenia. Finalization of the questions, their wording and
the approach to analysis of the survey results took place
during a series of steering committee meetings, funded
by Janssen, and with input from an independent com-
pany with prior experience in conducting surveys of the
perceptions of health care providers.
In order to maximize the reach of the survey and to
capture any potential geographical variations regarding
the perceptions and opinions of functioning in patients
with schizophrenia, psychiatrists were identified using a
database held by Janssen. Surveys were delivered by mail
(in Belgium, The Netherlands, Germany, Serbia, Spain,
France, UK and Switzerland) or by Janssen representa-
tives (in other countries). Psychiatrists received a sealed
pack containing the survey, a prepaid envelope and a
signed letter from the steering committee explaining
the aims of the survey. The survey was translated from
English into local languages when required. The survey
took approximately 10 min to complete. Surveys were
completed anonymously, and no individual patient data
were collected. Respondents to the survey provided in-
formed consent for the use of the results for research
purposes. A copy of the consent form is available for re-
view by the Editor-in-Chief of this journal. Completed
surveys were returned directly and blinded to an inde-
pendent third party for data analysis. The survey was
not designed to allow statistical analysis of the differ-
ences in responses. Interpretation of the results reported
here is based on qualitative comparison of the responses
obtained.
Results
Respondent demographics
Out of 31,570 surveys distributed, 4,163 were returned
from 42 countries in Europe, the Middle East and Africa
(Additional file 1) which reflects a response rate of 13%.
Fifty-two percent of respondents were male, and 39%
were female (9% did not respond to this question). Most
(62%) had 10 or more years' experience in schizophrenia,
and 30% had less than 10 years' experience (8% did not
respond to this question). Of those who responded to
specific questions regarding their place of work, 53% of
respondents worked in academic settings, 74% indicated
that their workplaces received public funding and 51%
indicated that their workplaces had both inpatient and
outpatient facilities (Additional file 2).
Extent of functioning impairments in patients with
schizophrenia
Based on an assessment of the last ten patients seen with
an established diagnosis of schizophrenia, psychiatrists es-
timated the number of patients with adequate, impaired
or very poor levels of functioning. An average of 70% of
patients were judged to have impaired or very poor levels
of functioning (Figure 1). This view was broadly shared
across all responders from Europe, the Middle East and
Figure 1 The level of functioning in patients with schizophrenia,
as estimated by psychiatrists.
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Africa (mean values ranged between countries from 55%
to 81%; data not presented here).
Importance of personal and social functioning as a
treatment goal
Based on a listing of response options of the most import-
ant treatment goals identified by the scientific committee,
53% of psychiatrists ranked ‘alleviate psychotic symptoms’
as the most important treatment goal (Figure 2). Enhan-
cing personal and social functioning was considered the
most important treatment goal by 17% of psychiatrists
treating patients with schizophrenia (Figure 2), ranking
third along with prevention of relapse.
Psychiatrists were asked to indicate their level of
agreement regarding the importance of social function-
ing as a treatment goal both for their patients and for
the families of patients with schizophrenia. Ninety-two
percent of psychiatrists agreed or strongly agreed that
social functioning is an important treatment goal for pa-
tients with schizophrenia, and 91% agreed or strongly
agreed that this is also an important goal for the families
of patients.
Assessment of personal and social functioning
To assess further how psychiatrists measured personal
and social functioning, respondents were asked whether
a patient's level of social functioning should be measured
regularly and recorded. The majority of psychiatrists
(84%) agreed or strongly agreed that a patient's level of
social functioning should be measured regularly and
recorded. Fifty-six percent of psychiatrists assessed per-
sonal and social functioning in patients with schizophre-
nia at every visit, 25% assessed functioning every two to
three visits, 12% assessed functioning two to three times
per year, 2% never assess or record functioning and 5%
did not respond (Additional file 3).
In order to determine how psychiatrists assessed per-
sonal and social functioning in their patients, respondents
were required to select from a list that included assess-
ment scales they used. The scientific committee consid-
ered that PSP, GAF and SOFAS were the most relevant
scales and the most important in clinical use, and as such
were used as the three options in this survey. When asked
which approach was most often used to assess a patient's
level of personal and social functioning, the majority
of psychiatrists surveyed (81%) used clinical interviews.
When asked specifically which scales they used most fre-
quently, 10% of psychiatrists used functioning scales, with
47% of these preferring to use the GAF scale, 25% prefer-
ring to use the PSP scale and 9% preferring to use the
SOFAS scale. The majority of psychiatrists (87%) agreed
or strongly agreed that obtaining a family member's opin-
ion on the patient's level of social functioning was import-
ant (Additional file 3).
In asking respondents whether it was clinically useful to
distinguish between improvement in symptoms and im-
provement in social functioning, the majority of psychia-
trists (85%) agreed or strongly agreed that it was clinically
relevant to distinguish between these clinical characteris-
tics. Fifty-six percent of respondents agreed or strongly
agreed that cognitive impairment and social functioning
should be assessed as two separate entities in patients with
schizophrenia, although 20% disagreed or strongly dis-
agreed with treating cognitive impairment and social func-
tioning as separate entities (Additional file 3). Sixty-seven
percent of participants agreed or strongly agreed that a
consensus or guideline on patient and social functioning
would be a useful tool in clinical practice.
Improvement of personal and social functioning
When asked during which stage of schizophrenia do
they focus most to improve their patients' social func-
tioning, the majority of psychiatrists (84%) focused most
on improving social functioning in their patients either
within 6 months of the onset of the illness or within 5
years of diagnosis (Additional file 3).
Figure 2 Psychiatrists' perceptions of the most important
treatment goals for patients with schizophrenia.
Figure 3 The patient behaviours on which psychiatrists
primarily based judgements regarding improvements in
social functioning.
Gorwood et al. Annals of General Psychiatry 2013, 12:8 Page 4 of 8
http://www.annals-general-psychiatry.com/content/12/1/8
Upon detection of a low level of social functioning in
patients with schizophrenia, the first step most commonly
taken by psychiatrists (41%) was to use a psychosocial
intervention, whereas many (34%) would reconsider the
patient's current drug therapy (Additional file 3). The sci-
entific committee viewed psychotherapy, pharmacological
treatment and the utilization of a psychosocial interven-
tion (e.g. social, psychological, psychoeducation) as the
most relevant strategies to manage and improve social
functioning in patients with schizophrenia. Forty-six per-
cent of respondents preferred to use psychosocial strat-
egies to manage and improve social functioning, while
26% favoured pharmacological strategies and 10% fa-
voured psychotherapy (Figure 3). Of the 4,163 psychia-
trists surveyed, 6% did not employ a specific strategy to
improve social functioning, and 10% did not answer
this question (Figure 3).
When asked how psychiatrists aimed to improve the so-
cial functioning of their patients with schizophrenia, 47%
of respondents reported that they most often ask a mem-
ber of the patient's family for support in improving their
patient's social functioning, whereas others (40%) would
seek the input of another health care professionals (HCPs)
within the multidisciplinary team (Additional file 3).
Following this, psychiatrists were asked on which patient
behaviours they primarily based their judgments regarding
improvements in social functioning. Improvements were
most commonly judged by changes in the patient's per-
sonal and social relationships (41% of respondents) or by
engagement in socially useful activities, such as work or
study (35%) (Figure 4).
Pharmacological strategies for improving personal and
social functioning
Altering the dose of the current antipsychotic was the
preferred pharmacological strategy used to address defi-
cits in social functioning (used by 35% of respondents)
followed by switching to another antipsychotic agent
(27%) or switching to another formulation (12%). The
addition of antidepressants (7%), another antipsychotic
(5%) or mood stabilizers (3%) was the least frequently
applied pharmacological strategy used by the psychia-
trists surveyed to address social functioning. There was
a strong agreement amongst the psychiatrists surveyed
that the most important factors in selecting a pharmaco-
logical agent to improve social functioning were efficacy
and tolerability (75% and 56% of respondents ranked this
as ‘very important,’ respectively) (Additional file 3).
Discussion
This survey gathered information on the perceptions
and opinions of psychiatrists across Europe, the Middle
East and Africa regarding the personal and social func-
tioning of patients with schizophrenia. The survey dem-
onstrated that a large proportion of patients with
schizophrenia were considered by their clinician as hav-
ing impaired personal and social functioning and that
the vast majority of psychiatrists believed that it was im-
portant to assess functioning on a regular basis.
This survey found that while psychiatrists believe im-
proving personal and social functioning to be an import-
ant treatment goal for patients and their families, they
ranked this behind ‘alleviating psychotic symptoms’ and
‘reducing aggression and hostility’ when asked to rank
the treatment goals for their patients with schizophrenia.
While symptomatic remission has been cited as an im-
portant precursor to functional remission [18,42], it does
not, however, guarantee improvements in functioning.
Rates of symptom remission normally exceed those of
good functional outcome [15]. A recent study of outpa-
tients with schizophrenia concluded that while almost
half were in symptomatic remission, only 10% had
attained adequate social and/or vocational functioning
[29]. Similarly, an open-label antipsychotic trial found
that remission status did not correlate with improve-
ments in positive or negative symptoms or in cognitive
functioning [43]. Considered alongside the growing body
of evidence that alleviation of symptoms may not correl-
ate with improvements in social functioning in patients
with schizophrenia, the findings of this survey suggest that
a change in psychiatrists' current awareness and percep-
tions is required regarding the importance of impairments
in social functioning in patients with schizophrenia.
Psychiatrists concurred that the measurement and re-
cording of social functioning on a regular basis is import-
ant, and most assess personal and social functioning at
every visit. However, relatively few psychiatrists use
specific scales for assessing functioning, with clinical inter-
view being the method of preference, and many respon-
dents also value the opinion of the patient's family. In this
survey, the GAF scale [38] was reported as being used
most often followed by the PSP scale [39], although other
scales (e.g. SOFAS [36], FROGS [37]) are also used in clin-
ical practice. Non-standardized methods of assessment
Figure 4 Psychiatrists' preferred strategies for managing and
improving social functioning.
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make cross-study comparison difficult, particularly as
scales differ in terms of the types of domains assessed, the
methods by which information is gathered and the level of
complexity of the assessment. An additional complicating
factor is the non-concordance between patients' and psy-
chiatrists' assessments of functioning levels [44]. These are
amongst several challenges facing psychiatrists when
assessing functioning in their daily clinical practice.
Others include difficulty in distinguishing functioning
deficits from the effects of negative symptoms [7,45]
and a frequent lack of distinction between quality of life
and functioning measures [7,46]. In addition, only a
relatively small number of randomized, controlled clin-
ical trials of antipsychotic agents have assessed social
functioning using a specific scale [7]. These aspects
have been explored further in a recent research initia-
tive [44,47]. In the current survey, improvements in
functioning were normally found to be judged via per-
sonal and social relationships or by engagement in ac-
tivities such as work and study. Although these
measures can be considered to be objective and there-
fore valid and more straightforward to measure, they
can also be influenced by external societal factors and
individual values. Even when using these ‘objective’
assessment measures, the subjective opinions of the
patient, family and psychiatrist will also inevitably form
part of the evaluation process [6]. Most participants in
this survey agreed that clinical guidelines on social
functioning would prove useful to their practice, while
opinions were more divided regarding the clinical need
to differentiate the assessment of cognitive impairments
and social functioning. This supports the suggestions
that the current lack of a consensus in the assessment
of functioning hinders the effective assessment of pa-
tient progress and subsequent improvement of out-
comes [18,48].
The results presented here suggest that the current
method most commonly used as a primary measure to
tackle functioning deficits in patients with schizophrenia
is psychosocial intervention. Approximately one third of
psychiatrists would reconsider the patient's pharmaco-
logical treatment as a first step. The pharmacological
strategies most often used were changing the dose of the
current antipsychotic or changing the antipsychotic.
Respondents appeared to attach only low priority to
switching antipsychotic formulation, including oral, oral
extended release or long-acting injectable formulations.
Conclusions
In conclusion, psychiatrists recognize that a large pro-
portion of their patients with schizophrenia have im-
paired personal and social functioning. Clinicians assess
and record functioning on a regular basis, although
there is no consensus on how these assessments should
be conducted. There was agreement that guidelines on
this topic would aid clinical practice. While the majority
of psychiatrists would implement psychosocial strategies
as an initial step in addressing functioning deficits, a
considerable number would choose to alter the patient's
pharmacological therapy (although few psychiatrists con-
sidered changing the antipsychotic formulation). Most
psychiatrists identify improvements in social functioning
as a key outcome for patients and their families. The ma-
jority also agreed that a distinction between symptom im-
provement and improvements in social functioning would
be clinically useful. Despite this and the literature evidence
suggesting a lack of correlation between improving symp-
toms and improving functioning, enhancing functioning
was rated as a less important treatment goal than reducing
psychotic symptoms. This may signify a need for increased
awareness amongst psychiatrists of the uncertain correl-
ation between improvements in symptoms and in social
functioning. These results also highlight that addressing
deficits in social and personal functioning in patients with
schizophrenia is an important area for further develop-
ment, where increased emphasis on functioning as a treat-
ment goal may enhance outcomes for patients. It is hoped
that the findings of this survey can contribute to the design
of activities and tools applicable to everyday clinical prac-
tice to improve the assessment and management of social
functioning in patients with schizophrenia.
Limitations
Methodological differences existed between countries in
survey distribution. Participants in the survey were selected
from those known to the sponsoring pharmaceutical com-
pany. However, all surveys were completed anonymously
and results collated by an independent organization.
The response rate to the survey was 13% (based on
the initial number of surveys produced). As such, the re-
spondents to the survey may have a greater awareness or
interest in the topic of functioning and therefore may
not fully represent the broader HCP population. Simi-
larly, the extent to which the demographics (in terms of
the sex, age and practice setting) of the responders to
the survey may systematically differ from psychiatrists
across Europe, the Middle East and Africa as a whole,
and the potential impact of this on the survey results is
not known.
Additional files
Additional file 1: Country of origin of survey respondents. Summary
of the country origin of the survey respondents.
Additional file 2: Respondent demographics. Overview of the
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